Haywood analyst Gianluca Tucci has maintained their bullish stance on WELL stock, giving a Buy rating yesterday.
Gianluca Tucci has given his Buy rating due to a combination of factors that highlight WELL Health Technologies Corp’s potential for growth and resilience. Despite the delay in filing Q4/24 financials due to accounting implications related to its subsidiary, Circle Medical, the company does not foresee a significant impact on its cash flow or resources. This situation, while presenting a negative headline, may offer a buying opportunity for investors with a long-term perspective.
Additionally, WELL Health Technologies Corp has reported impressive growth in key performance indicators (KPIs) for 2024, including a 32% increase in patient visits and a 41% rise in technology interactions. The company’s Canadian clinics have also shown strong growth, both organically and through acquisitions. Furthermore, WELL’s strategic move to acquire a majority interest in HEALWELL AI Inc. suggests a commitment to expanding its technological capabilities, which could enhance its competitive position in the healthcare sector.
According to TipRanks, Tucci is ranked #1102 out of 9396 analysts.
In another report released yesterday, Canaccord Genuity also maintained a Buy rating on the stock with a C$8.50 price target.